10-Q: Sharps Technology Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Strategic Shifts

Sharps Technology reported its Q2 2024 results, showing a net loss and ongoing challenges with commercialization, while also highlighting strategic partnerships and a potential asset acquisition.

Summary

• Sharps Technology, a pre-revenue medical device company, reported a net loss of $2.1 million for the three months ended June 30, 2024, and a net loss of $3.1 million for the six months ended June 30, 2024.
• The company has not generated significant revenue from syringe sales to date.
• Operating expenses totaled $1.9 million for the quarter and $3.8 million for the six-month period, primarily driven by research and development and general and administrative costs.
• The company's working capital was $978,400 as of June 30, 2024, which is not expected to be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Sharps is focusing on commercializing its safety syringe products and has entered into a sales and distribution agreement with Roncadelle Operations s.r.l.
• The company is also working towards an asset purchase agreement with Nephron Pharmaceuticals Corporation, which includes a non-refundable deposit of $1 million that was forfeited.
• Sharps completed a Reg A offering and warrant inducement program in the second quarter of 2024, raising approximately $3.5 million in gross proceeds.
• The company's stock is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price rule.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments like new partnerships and a supply agreement, but the significant financial challenges, going concern warning, and potential delisting from Nasdaq weigh heavily on the overall sentiment.

Positives

• The company entered into a cooperative sales and distribution agreement with Roncadelle, expanding its market reach.
• Sharps completed a Reg A offering and warrant inducement program, raising approximately $3.5 million in gross proceeds.
• The company shipped its first Securegard sales to a South American distributor in June 2024.
• The company is working towards an asset purchase agreement with Nephron, which could enhance its manufacturing capabilities.
• The company has a supply agreement with Stericare Solutions, LLC for 520 million units of 10ml PP Sologard syringes with expected revenues in excess of $50M.

Negatives

• The company has not generated significant revenue from syringe sales to date.
• The company's working capital is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• A $1 million non-refundable deposit for an asset purchase agreement was forfeited.
• The company's stock is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price rule.
• There are ongoing delays in the commercialization of the Sharps Provensa product line.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise sufficient financing.
• The company faces the risk of delisting from the Nasdaq Capital Market if it does not regain compliance with the minimum bid price rule.
• The closing of the Asset Purchase Agreement with Nephron is contingent on obtaining the necessary financing, and there is no assurance that the closing will occur.
• There are ongoing delays in the commercialization of the Sharps Provensa product line.
• The company has not generated significant revenue from syringe sales to date.

Future Outlook

The company intends to finance its commercialization activities and working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The company is also working towards an asset purchase agreement with Nephron and a supply agreement with Stericare Solutions, LLC.

Management Comments

• Management believes the company's ability to continue as a going concern is dependent upon the company's ability to raise sufficient financing.
• Management is working to amend the terms of the NPC Agreement based on the Amended Asset Purchase Agreement dated May 20, 2024.
• Management is currently negotiating its contract with O&M to provide 3PL services for both the Company and Roncadelle products, in North and South America, beginning in the third quarter of 2024.

Industry Context

The medical device industry is highly competitive, and Sharps Technology is facing challenges in commercializing its products. The company's strategic partnerships and potential asset acquisition are aimed at improving its market position and manufacturing capabilities. The company's focus on safety syringes aligns with the growing demand for safer medical devices.

Comparison to Industry Standards

• Sharps Technology is a pre-revenue company, which is not uncommon for early-stage medical device companies.
• The company's net losses are typical for companies in the development phase, but the lack of revenue and the going concern warning are significant concerns.
• The company's reliance on equity financing is common for pre-revenue companies, but the potential delisting from Nasdaq is a major setback.
• The company's strategic partnerships with Roncadelle and Nephron are similar to other companies in the industry that seek to expand their market reach and manufacturing capabilities.
• The supply agreement with Stericare Solutions, LLC is a significant development, as it provides a clear path to revenue generation.

Related Party Transactions

• As of June 30, 2024 and December 31, 2023, accounts payable and accrued liabilities include $114,000 and $32,974, respectively, payable to officers and directors of the Company.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern warning.
• Customers may be impacted by potential delays in product commercialization.
• Suppliers may face uncertainty due to the company's financial challenges.
• Creditors face increased risk due to the company's going concern warning.

Next Steps

• The company will continue to seek funding through equity offerings and/or debt financing opportunities.
• The company will continue to work towards the closing of the Asset Purchase Agreement with Nephron.
• The company will work to regain compliance with Nasdaq listing requirements.
• The company will commence the supply agreement with Stericare Solutions, LLC in November 2024.
• The company will continue to produce commercial quantities of its products and build inventory to support the Sales and Distribution Agreement with Roncadelle.

Key Dates

Keywords

medical devices, safety syringes, commercialization, manufacturing, distribution, financial results, going concern, capital raise, warrants, asset purchase, Roncadelle, Nephron, Nasdaq delisting